Last reviewed · How we verify
Sequential therapy for 10 days
The sequential therapy for 10 days, marketed by National Taiwan University Hospital, holds a niche position in the therapeutic landscape. The key composition patent expiring in 2028 provides a period of exclusivity, enhancing the drug's competitive edge. The primary risk lies in the lack of clear revenue data and key trial results, which may affect investor confidence and market adoption.
At a glance
| Generic name | Sequential therapy for 10 days |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma (PHASE1, PHASE2)
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) (PHASE3)
- A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma (PHASE3)
- CAR-T Followed by Bispecific Antibodies (PHASE2)
- Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM) (PHASE1)
- Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension (PHASE3)
- CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy (PHASE1, PHASE2)
- Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sequential therapy for 10 days CI brief — competitive landscape report
- Sequential therapy for 10 days updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI